在调节器时代的晚期囊性纤维化肺病的流行病学
Julia Westhoff1, Lutz Naehrlich
1Department of Pediatrics, Pediatric Pulmonology, Justus-Liebig-University, Giessen, Germany.
Current opinion in pulmonary medicine
|August 22, 2024
概括
高效的囊性纤维化跨膜调节器 (CFTR) 调节器显著改善了大多数晚期肺病患者的治疗结果. 现实世界的数据证实了安全性和降低死亡率,尽管对于一些人来说,替代治疗仍然是必要的.
科学领域:
- 肺部病理学 肺部病理学
- 医学遗传学 医学遗传学
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期囊性纤维化肺病是患有囊性纤维化 (pwCF) 个体的主要死亡原因.
- 囊性纤维化跨膜调节器 (CFTR) 调节器已经成为符合条件的pwCF的转化疗法.
- 这些调节剂对疾病负担和生存的影响是研究的一个关键领域.
研究的目的:
- 审查高效的三重CFTR调制剂疗法在晚期肺部疾病的pwCF中的现实世界的有效性和安全性.
- 评估CFTR调制剂对死亡率和肺移植率的影响.
- 确定pwCF的比例不符合当前调节器治疗的条件,以及需要替代治疗的需要.
主要方法:
- 综述现实世界数据,对晚期囊性纤维化肺病患者进行三重CFTR调节器治疗.
- 对安全概况,临床改善,死亡率和肺移植率的分析.
- 对当前CFTR调节器治疗的患者资格的评估.
主要成果:
- 现实世界的数据表明,在晚期囊性纤维化肺病中,高效的三重CFTR调节器疗法没有安全问题.
- 观察到的临床改善与一般的囊性纤维化病患者群体的改善相似或优于.
- 自CFTR调节剂,特别是三重疗法推出以来,死亡率和肺移植率的显著下降已被注意到.
结论:
- 高效的CFTR调节器疗法对大多数pwCF来说是一个突破,特别是那些晚期肺病患者.
- 这些疗法已经明显改善了生存率,并减少了疾病负担.
- 显著的一小部分pwCF仍然无法接受当前调节器疗法,这凸显了对替代治疗开发的持续需求.
相关概念视频
01:24Cystic Fibrosis: Management
148
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
148
01:23Cystic Fibrosis: Pathogenesis
198
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
198
01:20COPD: Pathogenesis and Clinical Features
246
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
246
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259
01:26COPD: Management Using Bronchodilators and Corticosteroids
190
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
190